Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Connect with us

News

MSD Africa Supports World Immunization Week

Published

on

Kindly share this post

MSD Africa has announced its support of World Immunization Week, an annual global initiative launched by the World Health Organization (WHO) and partners on April 20th to promote immunization for people of all ages through advocacy, education and communication.

WHO’s Africa Regional office (AFRO) has launched AFRO Immunization Week 2013 on 23 April to highlight the importance of protecting people in the region who are at significant risk of vaccine-preventable diseases.

The theme of this year’s World Immunization Week is ”Protect your world – get vaccinated.”

Vaccines have had a profound impact on public health. They help to prevent more than 30 common, yet potentially fatal, infectious diseases and to avert long-term disability and an estimated two to three million deaths worldwide each year.

However, the benefits of immunization need to extend beyond children, to reach adolescents and adults, and provide protection against life-threatening diseases such as influenza, meningitis and cervical cancer.

“Vaccines have not yet reached all those in the world who need them,” said Professor Dr Lynette Denny, Head of Department of Obstetrics and Gynaecology, Groote Schuur Hospital/University of Cape Town.

“World Immunization Week aims to reinforce the message that timely vaccination prevents disease and to mobilize action to improve vaccination coverage for the world’s at-risk individuals of all age groups.

This is particularly important with regard to cervical cancer, a disease that disproportionately afflicts women in developing countries, where 76 to 86 percent of all cases occur.”

Although there have been great successes with vaccination in Africa, many challenges remain. An estimated 22.4 million infants worldwide have not received the recommended three doses of diphtheria-tetanus-pertussis vaccine, with the majority of these infants coming from 10 countries, including Chad, Democratic Republic of the Congo, Ethiopia, Nigeria and South Africa. Further, more than 1.5 million children under the age of five – most of them in low-income countries – die from diseases that could be prevented by currently available vaccines.

“At MSD we are pleased to support World Immunization Week, which provides an important opportunity to raise awareness about the positive public health impact of vaccination,” said Soren Bo Christiansen, president, MSD, Eastern Europe, Middle East and Africa region.

“MSD is proud of its ongoing commitment to preventing these diseases worldwide. More than ever, we recognize that the value of vaccination has moved beyond the reduction of infant mortality, and is becoming an integral component of the provision of healthcare services, from infancy to old age, across the globe. It is our goal to press forward with innovative solutions to making vaccines available, limit potentially preventable deaths and improve quality of life. In Africa, MSD is pursuing a systematic and thoughtful approach to improve access to vaccines through four key pillars, innovation, partnerships, pricing and support with implementation.”


Kindly share this post

Dear Reader, Your support matters. But we believe that technology makes life more exciting and helps improve the lives of people around Nigeria and indeed the world. That is why, we have devoted our energy to independent reportage of technology and finance and how they affect lives. Our incisive and analytical view of how technology news affects the daily life help individuals and organizations make up their minds. Quality journalism costs money. Today, we're asking that you support us to do more. Kindly support our effort to deliver technology and finance journalism to everyone in the world. Donate as little as N1,000. Bank transfers can be made to: UBA Plc 1017156876 Communication Week Media Ltd

News

INTERPOL Report Shows Cybercrime is West, East African Most Dominant Security Concern

Published

on

Kindly share this post

Cybercrime has emerged as a dominant security concern across Africa, with more than 30 percent of all reported crimes in Western and Eastern regions linked to cyber activity, according to the newly released 2025 Africa Cyberthreat Assessment Report by INTERPOL.

The report, based on data from African member states and private sector partners, reveals that two-thirds of surveyed countries describe cybercrime as constituting a medium to high share of total criminal cases.

This highlights how cyber-enabled criminal activity is evolving rapidly across the continent. The report identified alarming spikes in scam attempts, with some countries witnessing a 3,000 percent increase in suspected scam notifications in the past year.

Neal Jetton, INTERPOL’s Cyber Crime Director, warned that the threat landscape is evolving faster than enforcement responses.

“This fourth edition of the INTERPOL African Cyber Threat Assessment provides a vital snapshot of the current situation, informed by operational intelligence, extensive law enforcement engagement, and strategic private-sector collaboration.

“It paints a clear picture of a threat landscape in flux, with emerging dangers like AI-driven fraud that demand urgent attention. No single agency or country can face these challenges alone,” Jetton stated.

In the past year, suspected scam notifications rose by up to 3,000 per cent in some African countries, according to data from Kaspersky, one of several private sector partners that work with INTERPOL’s cybercrime directorate

Online scams, particularly through phishing, are the most frequently reported cybercrimes across the continent. Ransomware attacks and Business Email Compromise (BEC) incidents are also increasing, particularly in Nigeria, Kenya, South Africa, and Egypt.

“Ransomware detections in Africa also rose in 2024, with South Africa and Egypt suffering the highest number, at 17,849 and 12,281 detections respectively, according to data from Trend Micro, followed by other highly digitised economies such as Nigeria (3,459) and Kenya (3,030),” it stated.

Incidents included attacks on critical infrastructure, such as a breach at Kenya’s Urban Roads Authority (KURA), and on government databases, such as hacks of Nigeria’s National Bureau of Statistics (NBS), the report stated.

 


Kindly share this post
Continue Reading

News

GSK to Slash Cost of Malaria Jab to Less than $5

Published

on

Kindly share this post

The manufacturers of the world’s first malaria vaccine are set to slash the price by more than half by 2028 to less than$5 per dose.

GSK to Slash Cost of Malaria Jab to Less than $5

The manufacturers of the shot, known as RTS,S, said a phased reduction in cost would begin immediately, with an ultimate aim to reduce the price to less than $5.

The announcement could hardly come at a more critical moment.

Gavi, a major vaccination initiative which funds immunisations in the world’s poorest countries, is facing a major budget crunch.

In Brussels on Wednesday, Gavi’s replenishment event raised $9 billion to fund immunisation programmes over the next five years. While this sounds like a huge sum, it’s significantly less than the $11.9bn the group had been aiming for.

Governments around the world are cutting development spending dramatically.

The UK, for instance, cut its contribution to Gavi by 40 per cent in real terms, telling The Telegraph it was prioritising defence, while the US has pledged nothing at all.

Though America previously gave Gavi roughly $300m a year, the country’s new health secretary claimed without evidence that the organisation was ignoring vaccine safety.

The announcement from the British pharmaceutical giant GSK and Indian drugmaker Bharat Biotech will therefore be a relief to those trying to balance the books.

In a statement the companies said the price reduction demonstrated their “commitment to Gavi”, and was “driven by process improvements, expanded production capacity, cost-effective manufacturing, and minimal profit margins”.

By the time the price has fallen to below $5 per dose, a technology transfer agreement means Bharat will have taken over production, though GSK will continue to supply the adjuvant piece of the shot.

“For us, this is more than a cooperation, it’s a promise,” said Dr Krishna Ella, executive chairman of Bharat Biotech International Limited.

“By joining forces with GSK, and working closely with Gavi, and the WHO [World Health Organization], we are taking a real step toward closing the gap between vaccine supply and the urgent needs of children at risk of malaria.”

Each year, malaria still kills 500,000 people – the vast majority of them children aged five and under in sub-Saharan Africa.

According to WHO estimates, cases and deaths fell significantly between 2000 and 2015, but progress has since stalled.

Some have high hopes that RTS,S, as well as another vaccine called R21 developed by Oxford University, could prove critical in efforts to turn the tide.

In clinical trials, RTS,S reduced hospitalisations for severe malaria by 30 per cent.

But critics say the shot is too expensive and not as effective as existing tools, such as bed nets and antimalarials.

The reduction in price will bring it more in line with the cost of R21, which is priced at around $4 per dose.

Yet the cost will still add up, as both jabs require multiple shots. For RTS,S, this means four doses – the first three doses are given monthly, starting around five months of age, while the fourth dose is administered 15-18 months later.

Both jabs “provide reasonable short term efficacy – over about a year – so are a useful addition to other measures,” said Professor Nick White, a professor at the Mahidol-Oxford Tropical Medicine Research Unit who specialises in malaria.

“In the past GSK had limited production capacity – one of the reasons the R21 was developed. So reducing the price will be good and the two comparable vaccines can fight it out in the market place.”

A spokesperson for Gavi said the alliance’s goal is to “create sustainable demand backed by predictable financing so that companies – like GSK and Bharat – can continue investing in technology transfer and other efficiencies that bring down costs, thus making critical vaccines more available and affordable.

GSK’s decision to lower its prices, the spokesperson added, is “an important step for the global malaria vaccination programme, and our ability to make this lifesaving tool more widely available to those who need it the most”.

Gavi plans to help fund RTS,S in 12 African countries by the end of this year.

Previously, GSK has said it will supply up to 18 million vaccine doses between 2023 and the end of this year.

The company plans to supply 15 million doses annually from 2026-2028, a spokesperson told Reuters.


Kindly share this post
Continue Reading

News

Rack Centre Signs Collocation Deal with TelCables Nigeria

Published

on

Kindly share this post

Rack Centre, West Africa’s Tier III carrier- and cloud-neutral data centre, has struck a collocation agreement with TelCables Nigeria, an Angola Cables subsidiary.

TelCables Nigeria is delivering its high-capacity network and cloud infrastructure, as well as four international subsea cable systems (SACS, MONET, SEBRAS, and EllaLink), directly into Rack Centre’s regional carrier ecosystem as part of the agreement.

According to Angola Cables, the move provides reliable, low-latency south-bound routes to Europe, the Americas, and Latin America, reducing the danger of future cable disruptions along West Africa’s coast and enabling next-generation cloud services across the continent.

“Our unique Africa – to – Latin America route via SACS, combined with MONET, SEBRAS and EllaLink, gives customers the lowest – latency paths to the Americas and Europe,” said Fernando Fernandes, CEO of TelCables Nigeria.

“Businesses in latency sensitive sectors: financial services, content delivery and real-time communications will experience faster transactions, reduced lag and an enhanced user experience.

“By hosting at Rack Centre we also localise Clouds2Africa resources, price them in naira, and remove expensive ingress/egress charges or FX exposure.”

Rack Centre said its 13.5MW data centre campus designed with its recently launched LGS2 facility that delivers a design PUE of 1.35 and powered from sustainable energy sources, already hosts 70+ carriers, ISPs and network operators.

Lars Johannisson, CEO of Rack Centre, commented: “Adding a global operator of Angola Cables’ calibre through TelCables Nigeria dramatically deepens our connectivity fabric.

“We can now offer 99.95 % SLA routes to more destinations, enabling enterprises, governments and cloud providers to meet performance and data-residency requirements while keeping traffic local.”

 


Kindly share this post
Continue Reading

Trending